Janux Therapeutics, Inc. — Form D
Janux Therapeutics, Inc. of La Jolla, CA, a company, filed a Form D exempt-offering notice with the SEC on 2020-07-14. The offering totals $15.9M, of which $11.4M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-07-14
- Form: D
- Accession: 0001817713-20-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $15.9M
- Amount sold: $11.4M
- Remaining: $4.5M
- Investors: 3
- Date of first sale: 2020-06-30
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-370889
Issuer
- Name: Janux Therapeutics, Inc.
- CIK: 0001817713
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 11099 TORREY PINES ROAD, La Jolla, CA, 92037
- Phone: 858-750-4700
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Tighe Reardon | Executive Officer | La Jolla, CA |
| Jay Lichter, Ph.D. | Director | La Jolla, CA |
| Sheila Gujrathi | Director | Boston, MA |
| Stefan Heller | Director | La Jolla, CA |
| Jake Simson, Ph.D. | Director | Carlsbad, CA |
| Peter Thompson, M.D. | Director | La Jolla, CA |
| Vickie L Capps | Director | La Jolla, CA |
| David Campbell, Ph.D. | Director | La Jolla, CA |
| David Campbell, Ph.D. | Executive Officer | La Jolla, CA |
Other filings by this issuer (2)
More